“Discovery and development of novel anti-diabetic drug candidate DBPR211 by antagonizing peripheral CB1 receptors” has been awarded the 18th National Innovation Award in the Renewal and Issue the Excelsior Award by the Research Center for Biotechnology and Medicine Policy.
